Previous 10 | Next 10 |
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND filings for antibody drug conjugates (ADCs), VIP943 and VIP924, remain o...
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma...
Clinical-stage biotech Vincerx Pharma (NASDAQ:VINC) announced on Tuesday that its Chief Medical Officer Hermes Garban would leave his position on or before Aug. 06 in connection with the recently announced strategic plan. Dr. Garban served as the head of Therapeutics Discovery and Development...
Vincerx Pharma (NASDAQ:VINC) on Monday said it would cut its workforce by 33% and would prioritize its resources on its ongoing trials for treatments for lymphoma and leukemia. The company said it would focus its resources on its VIP152 clinical studies for patients with double-hit diffu...
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in 2H23 remain on track Streamlining and realigning resources to support key ind...
Vincerx Pharma press release (NASDAQ:VINC): Q1 GAAP EPS of -$0.79 misses by $0.03. “Looking to the second half of this year and into 2023, we look forward to continuing to advance our preclinical bioconjugation platform – a diverse, modular platform of linkers and payloads that ...
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual Meeting Continues to execute on Phase 1b VIP152 clinical studies; on track to init...
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic cancers PALO ALTO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nas...
Vincerx Pharma press release (NASDAQ:VINC): Q4 GAAP EPS of -$0.31. Cash balance of $111.5M as of December 31, 2021. For further details see: Vincerx Pharma GAAP EPS of -$0.31
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in April 2022 Anticipate initiating Phase 2 studies of VIP152 in 2H2022 ...
News, Short Squeeze, Breakout and More Instantly...
Vincera Pharma Inc Com Company Name:
VINC Stock Symbol:
NASDAQ Market:
Vincera Pharma Inc Com Website:
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive result...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warra...